Several studies have also demonstrated that increasing T cell infiltrates in TME appear in patients with metastatic melanoma treated with BRAF/MEKi, enhancing a favorable anti-tumor microenvironment and decreasing immunosuppressive markers, which implies a higher survival rate [113,114,115,116]. The gene discussed is BRAF; the disease is metastatic melanoma.